DURECT Corporation (Nasdaq: DRRX) today announced the publication of a peer-reviewed article on the AHFIRM trial data in NEJM ...

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Durect (DRRX – Research Report) today. The company’s shares opened today at ...

H.C. Wainwright analyst Ed Arce keeps a Neutral rating on Durect (DRRX) without a price target after the company announced that data from the ...

Topline results from AHFIRM were previously announced by DURECT. "We are encouraged by the AHFIRM data and look forward to further assessing the benefits of larsucosterol in AH patients in a Phase ...

StockNews.com initiated coverage on shares of DURECT (NASDAQ:DRRX – Free Report) in a research note issued to investors on Tuesday. The firm issued a sell rating on the specialty pharmaceutical ...

Durect (DRRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates ...

Shares of DRRX opened at $0.84 on Wednesday. DURECT has a 12 month low of $0.68 and a 12 month high of $1.88. The stock’s 50 day moving average is $0.88 and its two-hundred day moving average is ...

CUPERTINO, CA - DURECT Corporation, a biopharmaceutical company with a market capitalization of $24.21 million, has been notified by the Nasdaq Stock Market of non-compliance with its minimum bid ...

CUPERTINO, CA - DURECT Corporation, a biopharmaceutical company with a market capitalization of $24.21 million, has been notified by the Nasdaq Stock Market of non-compliance with its minimum bid ...

The Health Foundation of South Florida, the region's largest philanthropic organization dedicated to improving community ...